

1 Off-season RSV epidemics in Australia after easing of COVID- 2 19 restrictions

3 John-Sebastian Eden^{1,2*}, Chisha Sikazwe^{3,4*}, Ruopeng Xie^{5,6*}, Yi-Mo Deng^{7,8}, Sheena G.
4 Sullivan^{7,9}, Alice Michie⁴, Avram Levy³, Elena Cutmore^{1,2}, Christopher C Blyth^{3,10-12}, Philip N
5 Britton^{2,13}, Nigel Crawford¹⁴⁻¹⁶, Xiaomin Dong^{7,8}, Dominic E. Dwyer^{2,17}, Kimberly M. Edwards^{5,6},
6 Bethany A. Horsburgh^{1,2}, David Foley³, Karina Kennedy¹⁸, Cara Minney-Smith³, David Speers^{3,10},
7 Rachel L. Tulloch^{1,2}, Edward C. Holmes², Vijaykrishna Dhanasekaran^{5,6#}, David W. Smith^{3,10#}, Jen
8 Kok^{17#} & Ian G. Barr^{7,8#} and the Australian RSV study group

9
10 ¹Centre for Virus Research, Westmead Institute for Medical Research, Westmead, NSW 2145, Australia

11 ²Marie Bashir Institute for Infectious Diseases and Biosecurity, Sydney Medical School, The University of
12 Sydney, Sydney, NSW 2006, Australia

13 ³PathWest Laboratory Medicine WA, Department of Microbiology, Nedlands, WA 6009, Australia

14 ⁴School of Biomedical Sciences, The University of Western Australia, Crawley, WA 6009, Australia

15 ⁵School of Public Health, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China

16 ⁶HKU-Pasteur Research Pole, School of Public Health, LKS Faculty of Medicine, The University of Hong
17 Kong, Hong Kong, China

18 ⁷WHO Collaborating Centre for Reference and Research on Influenza, Royal Melbourne Hospital, at the
19 Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria 3000, Australia

20 ⁸Department of Microbiology and Immunology, University of Melbourne, at the Peter Doherty Institute for
21 Infection and Immunity, Melbourne, Victoria 3000, Australia

22 ⁹Department of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and
23 Immunity, Melbourne, Victoria 3000, Australia

24 ¹⁰School of Medicine, The University of Western Australia, Crawley, WA 6009, Australia

25 ¹¹Department of Infectious Diseases, Perth Children's Hospital, Nedlands, WA 6009, Australia

26 ¹²Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, Nedlands, WA 6009,
27 Australia

28 ¹³Departments of Infectious Diseases and Microbiology, The Children's Hospital at Westmead, Westmead,
29 NSW 2145, Australia

30 ¹⁴Murdoch Children's Research Institute, Melbourne, Victoria 3000, Australia

31 ¹⁵Department of Paediatrics, University of Melbourne & Royal Children's Hospital, Melbourne, Victoria 3000,
32 Australia

33 ¹⁶Immunisation Service, Royal Children's Hospital, Melbourne, Victoria 3000, Australia

34 ¹⁷NSW Health Pathology - Institute for Clinical Pathology and Medical Research, Westmead Hospital,
35 Westmead, NSW 2145, Australia

36 ¹⁸Departments of Clinical Microbiology and Infectious Diseases, Canberra Hospital, Garran, ACT 2605,
37 Australia

38 Shared co-first* or co-senior# authorship

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

39 **Correspondence to:**

40 A/Prof Vijaykrishna Dhanasekaran (veej@hku.hk)

41 Prof David W. Smith (David.Smith@health.wa.gov.au)

42 Dr Jen Kok (jen.kok@health.nsw.gov.au)

43 Prof Ian G. Barr (ian.barr@influenzacentre.org)

44

45 **Keywords:** RSV, SARS-CoV-2, epidemic, genomic epidemiology, emergence, non-pharmaceutical
46 interventions

47 **Abstract**

48 Human respiratory syncytial virus (RSV) is an important cause of acute respiratory infection (ARI)
49 with the most severe disease in the young and elderly^{1,2}. Non-pharmaceutical interventions (NPIs)
50 and travel restrictions for controlling COVID-19 have impacted the circulation of most respiratory
51 viruses including RSV globally, particularly in Australia, where during 2020 the normal winter
52 epidemics were notably absent³⁻⁶. However, in late 2020, unprecedented widespread RSV
53 outbreaks occurred, beginning in spring, and extending into summer across two widely separated
54 states of Australia, Western Australia (WA) and New South Wales (NSW) including the Australian
55 Capital Territory (ACT). Genome sequencing revealed a significant reduction in RSV genetic
56 diversity following COVID-19 emergence except for two genetically distinct RSV-A clades. These
57 clades circulated cryptically, likely localized for several months prior to an epidemic surge in cases
58 upon relaxation of COVID-19 control measures. The NSW/ACT clade subsequently spread to the
59 neighbouring state of Victoria (VIC) and caused extensive outbreaks and hospitalisations in early
60 2021. These findings highlight the need for continued surveillance and sequencing of RSV and
61 other respiratory viruses during and after the COVID-19 pandemic as mitigation measures
62 introduced may result in unusual seasonality, along with larger or more severe outbreaks in the
63 future.

64 **Main**

65 Each year RSV causes an estimated 3.2 million hospital admissions and 118,200 deaths in
66 children under five years of age, predominantly in low- and middle-income countries⁷. While this
67 burden is greatest in the young, RSV is clinically significant for all age groups, as re-infection can
68 occur throughout life⁸. The elderly and immunocompromised are particularly at risk of severe
69 infection with intensive care admission and mortality rates similar to that of influenza, posing a
70 considerable threat to residents of long-term care facilities^{9,10}. RSV causes seasonal epidemics in
71 both tropical and temperate regions of the world¹¹. In Australia, most temperate regions experience
72 seasonal RSV outbreaks during the autumn and winter, often peaking in June-July¹² and usually
73 preceding the influenza season¹³. In the more tropical northern parts of Australia, RSV activity
74 correlates with the rainfall and humidity patterns of the rainy season from December to March¹⁴.

75
76
77 NPIs to limit the spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have
78 disrupted the typical seasonality of other common respiratory pathogens in many countries^{15,16}.
79 Australia's initial SARS-CoV-2 epidemic was effectively controlled by NPIs¹⁷, and those same
80 restrictions also suppressed seasonal respiratory virus circulation, particularly for influenza virus
81 and RSV, as the usual winter epidemics were notably absent during 2020³⁻⁵. While the control
82 measures of each Australian state and territory varied in stringency and duration¹⁸, all occurred

83 throughout the usual peak of RSV seasonal activity. Interestingly, the impact of NPIs was not
84 consistent across all the common respiratory viruses: rhinoviruses and, to a lesser extent,
85 adenoviruses continued to circulate in Australia during this pandemic period after an initial
86 disruption to usual circulation⁵. The suppression of influenza and RSV activity during the COVID-19
87 pandemic in the southern hemisphere was also seen in South Africa and New Zealand¹⁹, where
88 similarly following an initial reduction in circulation, RSV activity rebounded in late 2020²⁰ and early
89 2021, respectively. Marked reductions in RSV activity have also been seen in the northern
90 hemisphere since early 2020, although some European countries²¹ and US states²² have recently
91 reported out-of-season spikes in RSV activity in early-mid 2021. There has also been a dearth of
92 RSV sequences submitted to public databases since early 2020, presumably a reflection of the
93 lack of RSV circulation and a focus on SARS-CoV-2 sequencing.


94
95 In late 2020, severe out-of-season RSV outbreaks occurred in several Australian states and
96 territories beginning in New South Wales and the Australian Capital Territory (NSW/ACT) and
97 Western Australia (WA). This was followed by outbreaks in Victoria (VIC) throughout the summer
98 in early 2021. To understand the change in seasonal prevalence of RSV in Australia we examined
99 RSV testing data from January 2017 to March 2021, comparing the proportion positive and overall
100 testing capacity in NSW, WA, and VIC (Figures 1 & S1). Before 2020, RSV activity consistently
101 began during mid-autumn (April-May) and normally persisted for six months with an epidemic peak
102 in the middle of the Australian winter (middle of July, weeks 27 to 29). In contrast, RSV activity in
103 2020 occurred between six and nine months later than historically observed, and at the peak of
104 RSV activity across each state, laboratory-confirmed RSV positivity rates were considerably higher
105 than those of the previous three seasons (Figure 1).

106
107 In Australia, the suppression of RSV activity in early 2020 coincided with restrictions in
108 response to increasing community cases of COVID-19 (Figure 1). During March 2020, individual
109 Australian state and territory governments implemented a range of NPIs, which included limits on
110 international arrivals and strict quarantine requirements (for a minimum of 14 days), internal border
111 closures, social distancing, school closures or encouraging parents to keep their children home,
112 and hygiene protocols to minimise SARS-CoV-2 transmission. Importantly, and most relevant for
113 RSV, childcare centres mostly remained open during these restriction periods. Prior to the
114 implementation of these control measures, a gradual increase in RSV activity was observed in
115 early 2020 across all three states with laboratory test RSV positivity rates being similar to monthly
116 averages over the previous three seasons (Figure S1). The introduction of COVID-19 control
117 measures preceded the rapid decline in RSV incidence in each state. Examination of sentinel
118 hospital records for bronchiolitis by ICD-10 Australian modification (AM) codes (including both
119 RSV-confirmed bronchiolitis and bronchiolitis of unknown cause) showed a decline that mirrored

120 the decrease in laboratory-confirmed RSV (Figure S1). The subsequent RSV epidemics in late
121 2020 and early 2021 resulted in test positivity and ICD-10 AM admission levels equivalent to or
122 exceeding the normal winter seasonal RSV activity seen in any of the previous three years. For
123 NSW, the epidemic began in September 2020 with bimodal peaks in activity in mid-November
124 (reaching 26% positivity rate) and early January (reaching 24% positivity rate) (Figure 1). The dual
125 peaks likely reflect inconsistent testing over the Christmas holiday period, as the peak in
126 bronchiolitis hospitalisations in NSW occurred between late December and early January and
127 coincided with this period (Figure 1). Furthermore, a December 2020 peak was also observed in
128 the ACT, where 46% of tests were positive (data not shown). For WA, the RSV epidemic began in
129 late September and peaked in December at 37% positivity, with a matching peak in bronchiolitis
130 hospitalisations (Figure S1).

131

132 Over the course of the pandemic, the stringency of COVID-19 restrictions has varied
133 across the different states and territories. In VIC, a second wave of COVID-19 from July to August
134 2020 necessitated a longer SARS-CoV-2 control period, which likely contributed to a three-month
135 delay in the onset of RSV activity relative to epidemic outbreaks in NSW/ACT and WA. RSV
136 activity in VIC began in early January 2021 and then peaked in early March that year with 48% of
137 tests positive (Figure 1). In each state, the peaks in RSV activity occurred a few months after the
138 relaxation of COVID-19 restrictions (Figure 1).




139
140
141
142
143
144
145
146

Figure 1. The epidemiology of RSV detections in three Australian states. Laboratory testing for RSV in 2020 as weekly percent positive (red line, left y-axis) and as total number of tests performed (grey bars, right y-axis). In each panel, the dashed red line represents average monthly RSV percent positive over the three previous seasons, and corresponding red shading represents minimum and maximum weekly percent positive. Pink-shaded bars across the top of each plot indicate the severity of pandemic restrictions, with darker colours indicative of greater stringency. Blue bars across the top of each plot indicate the periods during which students did not attend school either due to pandemic restrictions or school holiday periods, with darker colours indicative of more stringent school restrictions.

147 Whole-genome sequencing was performed on RSV positive specimens collected before
148 (July 2017 to March 2020), during and after (April 2020 to March 2021) the implementation of
149 COVID-19 restrictions in NSW (n=253), ACT (n=47), WA (n=216), and VIC (n=178) (Figure 1C).
150 The samples were mostly collected from young children (median ages between 0.78 - 2.34 years
151 for the different states), although all age groups including adults and the elderly were represented.
152 Sampling of gender was even and included geographically diverse locations (Figures S2 & S3).
153 Historically in Australia, both RSV A & B subtypes have co-circulated in shifting but relatively even
154 prevalence^{23,24}. This trend continued in the pre-COVID-19 period, where RSV-A comprised
155 between 45% to 79% of cases. However, from late 2020 to early 2021 there was an overwhelming
156 predominance of the RSV-A subtype (>95% for all states). This suggested that RSV-A viruses
157 were responsible for both the NSW/ACT and WA outbreaks in late 2020, as well as, the surge in
158 RSV activity in VIC seen in early 2021.

159
160 Phylogenetic analysis of all the available RSV-A genomes revealed that the Australian
161 RSV-A viruses belonged to the ON1-like genotype first reported in Canada in December 2010²⁵.
162 These viruses have since become globally predominant and have frequently been re-introduced
163 into Australia^{23,26}. Indeed, prior to the emergence of SARS-COV-2 and the related control
164 measures, multiple RSV-A ON-1like sub-lineages co-circulated (Figure 2) with genetic diversity
165 sustained from both endemic and imported sources²³. While the viruses sampled before March
166 2020 were well-dispersed amongst those circulating globally, viruses from the post-COVID-19
167 period formed two geographically distinct monophyletic lineages (Figure 2A). One lineage was
168 associated with cases from NSW and ACT, while the other was associated with cases from WA,
169 and hereafter referred to as the NSW/ACT 2020 and WA 2020 lineages, respectively (Figure 2B).
170 Notably, both genetic lineages were defined by several key non-synonymous changes in the
171 genome. In the WA 2020 lineage, some changes were observed in the glycoprotein (T129I and
172 S174N), nucleocapsid (I104F) and small hydrophobic (H57Q) proteins, while significant non-
173 synonymous variation was observed in the NSW/ACT 2020 virus glycoprotein localised to the C-
174 terminus region (E263Q, L265P, S270P, Y273H, S277P, Y280H, S291P, Y297H, L310P, L314P,
175 and S316P), most of which do not appear to have been previously reported. The RSV-A outbreaks
176 occurred in NSW/ACT and WA during late 2020, and at that time, minimal RSV activity occurred in
177 other Australian states including VIC (Figure 1 & S1). However, genomic analysis showed that the
178 rise in cases in VIC in early 2021 was associated with multiple importations of the NSW/ACT 2020
179 lineage, with a small number of importations of the WA 2020 lineage, rather than the emergence of
180 another novel lineage (Figure 2A-B).

181



182

183

184

185

186

187

188

189

Figure 2. Phylogenetic analysis of global and Australian RSV-A genome sequences. (A) RSV-A genome sequences were aligned with NCBI GenBank reference sequences and analysed using a time-scaled maximum likelihood approach estimated with IQ-TREE focused on recent ON1-like viruses. Australian states and globally-derived sequences are colored according to the key provided. The light red line marks March 2020 and the beginning of extensive COVID-19 related restrictions. The blue shaded box is expanded in panel (B), which is a focused analysis of NSW/ACT and WA 2020 lineages. (C) Temporal signal in RSV-A genomic dataset determined by linear-regression of root-to-tip distance (y-axis) against sample collection date (x-axis).

190 To maximise spatiotemporal sampling of the RSV-A ON-1like viruses, we expanded our
191 phylogenetic analysis to all globally available RSV glycoprotein (G) sequences (Figure 3A), which
192 are more numerous than published whole RSV genomes. The genome-based phylogeny was
193 comprised of 1130 RSV-A ON1-like genomes (Figure 2A), while a further 1804 sequences were
194 included in the G protein phylogenetic analysis (Figure 3). Despite the additional sequences, the G
195 protein phylogeny found that the viruses from the 2020-2021 epidemics did not cluster with any
196 other viruses sampled nationally or internationally up to date. As such, the initial source of these
197 two novel RSV-A lineages remains undetermined (Figure 3A-B). Similar to the genome-scale
198 analysis, the G protein phylogeny also revealed that the genetic diversity of other ON1-like
199 lineages that co-circulated over the well-sampled period between 2016 and 2020 were absent
200 during these outbreak periods (Figure 3B). We also examined RSV-B diversity, and while the
201 number of detections were low, a similar pattern was observed to RSV-A diversity, whereby
202 previously established lineages were mostly absent, and a single lineage was dominant in the
203 2020-21 outbreak post-COVID-19 period (Figure S4). Taken together, these results illustrate a
204 remarkable collapse in the genetic diversity of RSV in Australia during the implementation of
205 COVID-19 related restrictions (Figure 3B).

206
207 The origins of these novel lineages remain unclear. Phylogenetic analysis suggests there was
208 sufficient genetic diversity within the outbreak samples to indicate circulation of these viruses in
209 NSW/ACT and WA prior to the release of COVID-19 restrictions (Figure 2B). Surveillance data
210 support this inference for the WA 2020 lineage; which was first detected in central and southern
211 non-Metropolitan regional WA from late July to September, and then in the Perth Metropolitan area
212 in October (Figure S3), indicating low-level circulation and rapid spread soon after introduction into
213 areas of high population density, in this case Metropolitan Perth. The genomic data also showed
214 two transcontinental transmissions from WA to VIC after November, at a time when interstate
215 travel bans had eased (Figures 2 & 3). In contrast, the origin and early dissemination of the
216 NSW/ACT 2020 lineage was less certain. Despite the widespread occurrence of outbreaks in NSW
217 and ACT, and the relatively high genetic diversity among the sub-lineages in this outbreak (Figure
218 2 & 3B), no precursor virus(es) of the same lineage were detected prior to the outbreak onset,
219 despite efforts to identify and sequence cases during the low activity period earlier in 2020. In
220 addition to a lack of RSV positive samples throughout the middle of 2020, our analysis was
221 hampered by an inflated evolutionary rate due to recent sampling²⁷, multiple novel non-
222 synonymous substitutions observed in the G protein, and a high amount of rate variation that
223 hampered reliable phylogenetic dating estimates. Therefore, we cannot rule out either hypothesis
224 that the viruses were already present in the country before the start of the COVID-19 pandemic or
225 that there were international incursions that occurred during the middle of 2020 when COVID-19
226 restrictions were in place.




Figure 3. Phylogenetic analysis of global and Australian RSV-A glycoprotein sequences. (A) RSV-A sequences in this study were aligned with all available RSV-A sequences from NCBI GenBank, and the glycoprotein coding region was extracted and sequences less than 300 nt were removed. (B) A detailed examination of recently circulating ON1-like viruses showed pre-COVID-19 lineages (colored red) had collapsed to only two in the post-COVID-19 period (blue) that were associated with outbreaks in NSW/ACT and WA in late 2020. No sequences sourced globally (yellow) were found to be related to the NSW/ACT and WA 2020 lineages suggesting the sources remain unknown. Diamonds at nodes indicate bootstrap support values >70%. Branches are proportional to the number of nucleotide substitutions per site.

235 An examination of RSV diversity in Australia before and after the implementation of COVID-
236 related NPIs using whole genome sequencing has shown a major collapse in circulating lineages
237 observed prior to 2020^{23,26}. This also coincided with the emergence of two distinct but
238 phylogenetically related RSV-A lineages associated with the summer outbreaks in NSW/ACT and
239 WA, respectively. Both these lineages were found to seed new outbreaks in VIC during early 2021.
240 Our analysis suggests the cryptic circulation of both lineages, while other RSV-A and -B lineages
241 were largely eliminated through COVID-19 related NPIs. While the estimation of the location of
242 origins of the epidemic was hindered by a paucity of sequence data from other jurisdictions and
243 globally, the genetic diversity observed during these outbreaks strongly indicates a localized
244 undetected circulation prior to the widespread outbreak; showing that travel restrictions and other
245 social distancing measures may have significantly reduced RSV transmission and slowed spread,
246 but were unable to eliminate RSV in metropolitan WA and in NSW, and after a considerable delay
247 a strong out-of-season epidemic occurred.

248
249 The near absence and subsequent resurgence of RSV-A in Australia has provided a unique
250 opportunity to increase our understanding about how RSV epidemics occur and to identify
251 measures for better control of RSV and other respiratory viruses in the future. Our study highlights
252 how quickly respiratory pathogens can rebound, even leading to unseasonal epidemics. Delayed
253 or forgone RSV seasons may increase the cohort of young children susceptible to RSV infection
254 and increase the age of first infection leading to more frequent and larger outbreaks of RSV when
255 they do finally occur. Indeed, delaying the age at first infection may be expected to coincide with
256 reduced hospitalisations given this burden is most pronounced in infants less than 6 months old²⁸;
257 however, this has not been reflected in bronchiolitis admissions (Figure S1), with peak admissions
258 in WA and VIC higher than in prior seasons. By increasing the pool of susceptible children,
259 including those with underlying risk factors such as congenital heart disease and extreme
260 prematurity or chronic lung disease, outbreaks may also be more severe with regards to
261 hospitalisations and intensive care admissions. Indeed, recent modelling studies predicted delayed
262 and severe RSV outbreaks in the US during winter of 2021-2022¹⁵ but not early out-of-season
263 outbreaks. It remains to be seen whether these large summer epidemics experienced in
264 NSW/ACT, WA and VIC have sufficiently reduced the susceptible population to result in a smaller
265 than usual winter season in 2021, although early winter data appears to support this premise.

266
267 It remains unclear how long it will take for normal winter RSV seasonality to resume. The H1N1
268 2009 influenza pandemic impacted on respiratory virus circulation for a number of years²⁹. The
269 findings from this study exemplify the need to be prepared for the occurrence of large outbreaks of
270 RSV outside of normal seasonal periods and for health systems to be prepared to combat future
271 severe RSV outbreaks. It also raises important questions as to how the epidemiological and

272 evolutionary dynamics of RSV outbreaks might inform the re-emergence of influenza virus, which
273 is still expected, and given the smaller role children play in population-scale transmission, may
274 require re-opening of international borders to import the variants required to effectively seed new
275 local outbreaks. Nonetheless, our study highlights the power of COVID-19-related NPIs to cause
276 immense disruption in seasonal patterns of respiratory virus circulation and evolution. Furthermore,
277 this study provides a timely warning to countries emerging from pandemic restrictions that the
278 burden of disease from other respiratory pathogens that may have all but disappeared, will likely
279 rebound in the near future, possibly at unusual times and with higher magnitude of cases.

280 **Methods**

281 *RSV surveillance and epidemiology*

282 Respiratory specimen testing with quantitative RT-PCR assays was performed at six sites
283 including i) NSW Health Pathology - Institute of Clinical Pathology and Microbiology Research
284 (ICPMR), Westmead, NSW, ii) The Children's Hospital at Westmead, NSW, iii) PathWest
285 Laboratory Medicine WA, Perth, WA³⁰, iv) The Royal Children's Hospital, Melbourne, VIC, v)
286 Monash Pathology, Monash Medical Centre, Clayton, VIC and vi) ACT Pathology, Canberra, ACT.
287 NSW Health Pathology - ICPMR and PathWest laboratories are both major diagnostic hubs that
288 provide state-wide testing for respiratory viruses in NSW and WA, respectively, Monash Pathology
289 provides services for all ages for a region of Melbourne, while the Children's Hospital at Westmead
290 and Royal Children's Hospitals are major metropolitan hospitals in NSW and VIC, respectively.
291 ACT Pathology provides diagnostic services for all adult and paediatric hospital emergency
292 department presentations and a proportion of outpatient community requests for the ACT. Weekly
293 counts for RSV testing were collated for the period January 2017 to March 2021, and derived from
294 three laboratories: PathWest Laboratory in Perth, WA, NSW Health Pathology - ICPMR in Sydney,
295 NSW, ACT Pathology, Canberra, ACT, and the Bio21 Royal Children's Hospital in Melbourne, VIC.
296 PathWest, ICPMR and ACT Pathology are public health laboratories testing children and adults
297 across their respective states, whereas Bio21 only provided testing data for children receiving care
298 at the Royal Children's Hospital in Melbourne, and therefore only includes results for children aged
299 under 18 years. The proportion of tests that were RSV positive was calculated and smoothed using
300 a 3-week, centred moving average. Data were plotted in time series to compare observed RSV
301 activity for April 2020 to March 2021, versus the average for April 2017 to March 2020. Monthly
302 bronchiolitis admissions for the 3 children's hospitals in Perth, Sydney and Melbourne were
303 collated for the period January 2017 to March 2021. Only admissions with a J21 ICD-10 AM code
304 were considered. Prior work has shown that admissions for bronchiolitis are heavily represented by
305 children aged <2 years. School and other restrictions for each state were collated from media
306 releases and official public health directions issued in each of the three states. In addition, school
307 holiday periods for all years January 2017 to March 2021 were collated to visually assess the role
308 of school holidays as a proxy for student mixing in RSV seasonality. The period between relaxation
309 of restrictions and increased RSV activity was visually compared.

310

311 *RSV subtyping and whole genome sequencing*

312 Samples were sequenced from cases collected for routine diagnostic purposes as part of public
313 health responses, and from on-going research studies approved by the local Human Research
314 Ethics Committees of the Royal Children's Hospital and Western Sydney Local Health District with
315 approval numbers 37185 and LNR/17/WMEAD/128, respectively. Total nucleic acid was extracted
316 from RSV positive respiratory specimens archived at -80°C using high-throughput bead-based

317 protocols. RSV whole genome sequencing (WGS) was conducted using established protocols²⁴ for
318 a subset of samples selected to provide temporal and geographical representation of i) the pre-
319 COVID-19 period, inclusive of July 2017 to March 2020, and ii) the post-COVID-19 period,
320 inclusive of April 2020 to March 2021. Briefly, viral cDNA was prepared from extracted nucleic acid
321 using SuperScript IV VILO Master Mix or SuperScript IV (Invitrogen, Carlsbad, CA, USA), followed
322 by RT-PCR amplification of four long overlapping fragments spanning the RSV genome using
323 Platinum SuperFi Master Mix (Invitrogen). The four target amplicons were then combined equally
324 before DNA purification with AMPure XP (Beckman Coulter, Indianapolis, IN, USA). The purified
325 and pooled amplicons were diluted to 0.2 ng/μl and prepared for sequencing using the Nextera XT
326 library preparation kit with v2 indexes (Illumina, San Diego, CA, USA). Multiplexed libraries were
327 then sequenced either on an Illumina iSeq 100 or MiSeq producing at least 200,000 paired end
328 reads (2x150nt) per library. For genome assembly, the sequence reads were QC trimmed using
329 BBDuk v37.98³¹ before *de novo* assembly with MEGAHIT v1.1.3³² or reference based assembly
330 with IRMA³³. To confirm assembly, the trimmed sequence reads were re-mapped onto the draft
331 genome with BMap v37.98 and visually assessed using the Geneious Prime v.2020.0.3 before
332 the final majority consensus genome was extracted. The sequences generated in this study have
333 been deposited in GISAID (Table S1).

334

335 *Phylogenetic analysis*

336 RSV sequences generated in this study were analysed along with reference sequences sourced
337 from the NCBI GenBank database or from the NIAID Virus Pathogen Database and Analysis
338 Resource (ViPR)³⁴ at <http://www.viprbrc.org/>. Specifically, all available full-length genomes and
339 partial G gene sequences (greater than 300 nt) with collection dates were downloaded on 22
340 March 2021. Multiple sequence alignments were performed independently with MAFFT v.7³⁵ and
341 examined using TempEst v.1.5³⁶ to identify and exclude excessively divergent sequences in a
342 preliminary maximum likelihood (ML) tree generated in FastTree v.2.1³⁷. Phylogenetic relationships
343 of the full-length alignments were inferred using the ML method in IQ-TREE v.2.0³⁸ using the best-
344 fit nucleotide substitution model and dated using the Least Squares Dating (LSD) method³⁹.
345 Ultrafast bootstrap approximation (UFBoot) and SH-like approximate likelihood ratio test (SH-
346 aLRT) was applied to estimate branch support. G gene phylogenies were estimated using RAxML
347 v.8⁴⁰ using the GTR-Γ nucleotide substitution model, with branch support estimated by 1000
348 bootstrap replicates.

349 **Acknowledgements**

350 Members of the RSV study group include Annette Alafaci, Ian Carter, Andrew Daly, Michelle
351 Francis, Alison Kesson, Hannah Moore, Christine Ngo & Tyna Tran.

352

353 **Funding**

354 The WHO Collaborating Centre for Reference and Research on Influenza is supported by the
355 Australian Government Department of Health. Funding was provided through the ICPMR Private
356 Practice Trust fund, the National Health and Medical Research Council Center of Research
357 Excellence in Emerging Infectious Diseases (1102962) and the Marie Bashir Institute for Infectious
358 Diseases and Biosecurity at the University of Sydney.

359 **References**

- 360 1. Falsey, A. R., Hennessey, P. A., Formica, M. A., Cox, C. & Walsh, E. E. Respiratory syncytial
361 virus infection in elderly and high-risk adults. *N. Engl. J. Med.* **352**, 1749–1759 (2005).
- 362 2. Hall, C. B. *et al.* The burden of respiratory syncytial virus infection in young children. *N. Engl.*
363 *J. Med.* **360**, 588–598 (2009).
- 364 3. Britton, P. N. *et al.* COVID-19 public health measures and respiratory syncytial virus. *Lancet*
365 *Child Adolesc Health* **4**, e42–e43 (2020).
- 366 4. Yeoh, D. K. *et al.* The impact of COVID-19 public health measures on detections of influenza
367 and respiratory syncytial virus in children during the 2020 Australian winter. *Clin. Infect. Dis.*
368 (2020) doi:10.1093/cid/ciaa1475.
- 369 5. Sullivan, S. G. *et al.* Where has all the influenza gone? The impact of COVID-19 on the
370 circulation of influenza and other respiratory viruses, Australia, March to September 2020.
371 *Euro Surveill.* **25**, (2020).
- 372 6. McNab, S. *et al.* Changing Epidemiology of Respiratory Syncytial Virus in Australia - delayed
373 re-emergence in Victoria compared to WA/NSW after prolonged lock-down for COVID-19.
374 *Clin. Infect. Dis.* (2021) doi:10.1093/cid/ciab240.
- 375 7. Shi, T. *et al.* Global Disease Burden Estimates of Respiratory Syncytial Virus-Associated
376 Acute Respiratory Infection in Older Adults in 2015: A Systematic Review and Meta-Analysis.
377 *J. Infect. Dis.* **222**, S577–S583 (2020).
- 378 8. Griffiths, C., Drews, S. J. & Marchant, D. J. Respiratory Syncytial Virus: Infection, Detection,
379 and New Options for Prevention and Treatment. *Clin. Microbiol. Rev.* **30**, 277–319 (2017).
- 380 9. Fleming, D. M. *et al.* Modelling estimates of the burden of Respiratory Syncytial virus infection
381 in adults and the elderly in the United Kingdom. *BMC Infect. Dis.* **15**, 443 (2015).
- 382 10. Lee, N. *et al.* High morbidity and mortality in adults hospitalized for respiratory syncytial virus
383 infections. *Clin. Infect. Dis.* **57**, 1069–1077 (2013).
- 384 11. Li, Y. *et al.* Global patterns in monthly activity of influenza virus, respiratory syncytial virus,
385 parainfluenza virus, and metapneumovirus: a systematic analysis. *Lancet Glob Health* **7**,
386 e1031–e1045 (2019).

- 387 12. Saravanos, G. L. *et al.* Respiratory syncytial virus-associated hospitalisations in Australia,
388 2006-2015. *Med. J. Aust.* **210**, 447–453 (2019).
- 389 13. Price, O. H., Sullivan, S. G., Sutterby, C., Druce, J. & Carville, K. S. Using routine testing data
390 to understand circulation patterns of influenza A, respiratory syncytial virus and other
391 respiratory viruses in Victoria, Australia. *Epidemiol. Infect.* **147**, e221 (2019).
- 392 14. Fagan, P., McLeod, C. & Baird, R. W. Seasonal variability of respiratory syncytial virus
393 infection in the Top End of the Northern Territory (2012-2014): Seasonality of RSV in the NT.
394 *J. Paediatr. Child Health* **53**, 43–46 (2017).
- 395 15. Baker, R. E. *et al.* The impact of COVID-19 nonpharmaceutical interventions on the future
396 dynamics of endemic infections. *Proc. Natl. Acad. Sci. U. S. A.* **117**, 30547–30553 (2020).
- 397 16. Olsen, S. J. *et al.* Decreased influenza activity during the COVID-19 pandemic-United States,
398 Australia, Chile, and South Africa, 2020. *Am. J. Transplant* **20**, 3681–3685 (2020).
- 399 17. Rockett, R. J. *et al.* Revealing COVID-19 transmission in Australia by SARS-CoV-2 genome
400 sequencing and agent-based modeling. *Nat. Med.* **26**, 1398–1404 (2020).
- 401 18. corporateName=Commonwealth Parliament, address=Parliament House, Canberra, ACT &
402 contact=+. COVID-19: a chronology of state and territory government announcements (up until
403 30 June 2020) – Parliament of Australia.
404 [https://www.aph.gov.au/About_Parliament/Parliamentary_Departments/Parliamentary_Library/
405 pubs/rp/rp2021/Chronologies/COVID-19StateTerritoryGovernmentAnnouncements](https://www.aph.gov.au/About_Parliament/Parliamentary_Departments/Parliamentary_Library/pubs/rp/rp2021/Chronologies/COVID-19StateTerritoryGovernmentAnnouncements).
- 406 19. Huang, Q. S. *et al.* Impact of the COVID-19 nonpharmaceutical interventions on influenza and
407 other respiratory viral infections in New Zealand. *Nat. Commun.* **12**, 1001 (2021).
- 408 20. SOUTH AFRICA WEEK. Weekly respiratory pathogens surveillance report.
409 [https://www.nicd.ac.za/wp-content/uploads/2020/12/Weekly-Respiratory-Pathogens-Report-
410 Week-50-2020.pdf](https://www.nicd.ac.za/wp-content/uploads/2020/12/Weekly-Respiratory-Pathogens-Report-Week-50-2020.pdf).
- 411 21. Casalegno, J.-S. *et al.* Delayed start of the respiratory syncytial virus epidemic at the end of
412 the 20/21 northern hemisphere winter season, Lyon, France. *bioRxiv* (2021)
413 doi:10.1101/2021.03.12.21253446.
- 414 22. RSV National Trends. <https://www.cdc.gov/surveillance/nrevss/rsv/natl-trend.html> (2021).

- 415 23. Robertson, M. *et al.* The spatial-temporal dynamics of respiratory syncytial virus infections
416 across the east-west coasts of Australia during 2016-17. *bioRxiv* 2020.11.06.372177 (2020)
417 doi:10.1101/2020.11.06.372177.
- 418 24. Di Giallonardo, F. *et al.* Evolution of Human Respiratory Syncytial Virus (RSV) over Multiple
419 Seasons in New South Wales, Australia. *Viruses* **10**, (2018).
- 420 25. Eshaghi, A. *et al.* Genetic variability of human respiratory syncytial virus A strains circulating in
421 Ontario: a novel genotype with a 72 nucleotide G gene duplication. *PLoS One* **7**, e32807
422 (2012).
- 423 26. Otieno, J. R. *et al.* Whole genome analysis of local Kenyan and global sequences unravels the
424 epidemiological and molecular evolutionary dynamics of RSV genotype ON1 strains. *Virus*
425 *Evol* **4**, vey027 (2018).
- 426 27. Duchêne, S., Holmes, E. C. & Ho, S. Y. W. Analyses of evolutionary dynamics in viruses are
427 hindered by a time-dependent bias in rate estimates. *Proc. Biol. Sci.* **281**, 20140732 (2014).
- 428 28. Nair, H. *et al.* Global burden of respiratory infections due to seasonal influenza in young
429 children: a systematic review and meta-analysis. *Lancet* **378**, 1917–1930 (2011).
- 430 29. Mak, G. C., Wong, A. H., Ho, W. Y. Y. & Lim, W. The impact of pandemic influenza A (H1N1)
431 2009 on the circulation of respiratory viruses 2009-2011. *Influenza Other Respi. Viruses* **6**, e6-
432 10 (2012).
- 433 30. Chidlow, G. R., Harnett, G. B., Shellam, G. R. & Smith, D. W. An economical tandem multiplex
434 real-time PCR technique for the detection of a comprehensive range of respiratory pathogens.
435 *Viruses* **1**, 42–56 (2009).
- 436 31. BBMap. <https://sourceforge.net/projects/bbmap/>.
- 437 32. Li, D., Liu, C.-M., Luo, R., Sadakane, K. & Lam, T.-W. MEGAHIT: an ultra-fast single-node
438 solution for large and complex metagenomics assembly via succinct de Bruijn graph.
439 *Bioinformatics* **31**, 1674–1676 (2015).
- 440 33. Shepard, S. S. *et al.* Viral deep sequencing needs an adaptive approach: IRMA, the iterative
441 refinement meta-assembler. *BMC Genomics* **17**, 708 (2016).

- 442 34. Pickett, B. E. *et al.* ViPR: an open bioinformatics database and analysis resource for virology
443 research. *Nucleic Acids Res.* **40**, D593-8 (2012).
- 444 35. Katoh, K. & Standley, D. M. MAFFT multiple sequence alignment software version 7:
445 improvements in performance and usability. *Mol. Biol. Evol.* **30**, 772–780 (2013).
- 446 36. Rambaut, A., Lam, T. T., Max Carvalho, L. & Pybus, O. G. Exploring the temporal structure of
447 heterochronous sequences using TempEst (formerly Path-O-Gen). *Virus Evol* **2**, vew007
448 (2016).
- 449 37. Price, M. N., Dehal, P. S. & Arkin, A. P. FastTree 2 – Approximately Maximum-Likelihood
450 Trees for Large Alignments. *PLoS ONE* vol. 5 e9490 (2010).
- 451 38. Minh, B. Q. *et al.* IQ-TREE 2: New Models and Efficient Methods for Phylogenetic Inference in
452 the Genomic Era. *Mol. Biol. Evol.* **37**, 1530–1534 (2020).
- 453 39. To, T.-H., Jung, M., Lycett, S. & Gascuel, O. Fast Dating Using Least-Squares Criteria and
454 Algorithms. *Syst. Biol.* **65**, 82–97 (2016).
- 455 40. Stamatakis, A. RAxML version 8: a tool for phylogenetic analysis and post-analysis of large
456 phylogenies. *Bioinformatics* **30**, 1312–1313 (2014).